Relationship between MPA free fraction and free MPAG concentrations in heart transplant recipients based on simultaneous HPLC quantification of the target compounds in human plasma

Cussonneau, Xavier; Bolon-Larger, Magali; Prunet-Spano, Céline; Bastien, Olivier; Boulieu, Roselyne

doi:10.1016/j.jchromb.2007.02.038

Cited by 14 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HPLC-ultraviolet assays can be calibrated to the low concentrations needed to measure the free fraction (Ͻ2% of total concentrations) but are generally less robust at these concentrations than HPLC-MS assays (115,116). Method accuracy data are a guide only, because comparison of the published data is complicated by use of a variety of different statistical approaches.…”

Section: Analytical Methods To Measure Mpa Concentrationsmentioning

confidence: 99%

Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation

Kuypers¹,

Meur²,

Cantarovich³

et al. 2010

Clinical Journal of the American Society of Nephrology

285

252

View full text Add to dashboard Cite

Section: Analytical Methods To Measure Mpa Concentrationsmentioning

confidence: 99%

Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation

Kuypers¹,

Meur²,

Cantarovich³

et al. 2010

Clinical Journal of the American Society of Nephrology

285

252

View full text Add to dashboard Cite

“…In our study, the albumin concentration in 51 patients was 35.1 6 5.2 g/L, which is similar to that in renal (35.1 6 1.3 g/L) and heart transplant (40.0 6 1.3 g/L) recipients. 12, 14 We did not find any patients with unexpected low albumin levels, which may be the result of the fact that most of the patients were given albumin to maintain an adequate plasma albumin level. When the albumin level was in the reference interval, its impact on the level of MPA free fraction was limited.…”

Section: Discussionmentioning

confidence: 69%

“…[10][11][12] Previous studies on pharmacokinetics of fMPA focused on renal or heart transplant recipients. [11][12][13][14] However, there is no similar study on liver transplant patients. Most of patients after liver transplantation have abnormal hepatic function, especially during the early stage posttransplant.…”

Section: Introductionmentioning

confidence: 99%

Establishment of High-Performance Liquid Chromatography and Enzyme Multiplied Immunoassay Technology Methods for Determination of Free Mycophenolic Acid and Its Application in Chinese Liver Transplant Recipients

Chen¹,

Gu²,

Chen³

et al. 2010

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

The objective of this study is to investigate the correlation between methods of high-performance liquid chromatography (HPLC) and enzyme multiplied immunoassay technology (EMIT) for determination of total mycophenolic acid (tMPA) and free (fMPA) concentration and to study pharmacokinetics of fMPA in Chinese liver transplant recipients. An HPLC method with fluorometric detection and an EMIT assay were established to determine fMPA in plasma ultrafiltrates. Pharmacokinetic parameters of tMPA and fMPA in 51 patients were estimated. The calibration range of fMPA was 0.0025 to 1.0 μg/mL for the HPLC method and 0.0050 to 0.50 μg/mL for the EMIT method. Mean recovery of the two methods was 98.0% and 97.1%, respectively. The intraday and interday coefficient of variations were 0.93% to 3.1% and 1.6% to 2.9% for HPLC and 4.51% to 15.8% and 5.83% to 19.5% for EMIT, respectively. The relationship of the two methods was EMIT = 1.074 × HPLC + 0.582 (r2 = 0.918, n = 470, P < 0.05) for tMPA and EMIT = 1.068 × HPLC + 0.004 (r2 = 0.945, n = 297, P < 0.05) for fMPA. There was a positive mean bias of EMIT for tMPA (27.0%) and fMPA (23.3%). The AUC0-12 of tMPA and fMPA obtained by HPLC in 51 patients was 34.7 ± 11.1 and 0.72 ± 0.38 μg·h/mL, respectively. The free fraction of MPA was 1.60 ± 1.21% (Median:1.36%, interquartile: 0.72, 2.22), [corrected] which was significantly correlated with 7-O-glucuronide conjugate of MPA AUC0-12 (r2 = 0.705, P < 0.001), albumin (r2 = -0.529, P < 0.001), and the clearance of creatinine (r2 = -0.417, r2 = 0.005). Both HPLC and EMIT assay are suitable for the determination of fMPA. A considerable interindividual variability exists in pharmacokinetics of fMPA among Chinese liver transplant recipients. 7-O-Glucuronide conjugate of MPA and albumin concentrations are two factors correlated to fMPA variance.

show abstract

“…Evaluation of free MPAG may be helpful for clarifying the influence of cyclosporine on free MPA, because MPAG can increase free MPA through displacement from its albumin-binding site (10,27). So far, some reports on free MPAG in kidney transplant recipients have been available (27)(28)(29); however, only Atcheson et al evaluated pharmacokinetic difference in free MPAG between CNI medications (28). Influence of cyclosporine on free MPAG was not fully characterized.…”

Section: Is Known and Objectivementioning

confidence: 99%

Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase

Mino

Naito

Otsuka

et al. 2011

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

Relationship between MPA free fraction and free MPAG concentrations in heart transplant recipients based on simultaneous HPLC quantification of the target compounds in human plasma

Cited by 14 publications

References 23 publications

Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation

Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation

Establishment of High-Performance Liquid Chromatography and Enzyme Multiplied Immunoassay Technology Methods for Determination of Free Mycophenolic Acid and Its Application in Chinese Liver Transplant Recipients

Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase

Contact Info

Product

Resources

About